Glycosylation-independent targeting enhances enzyme delivery to lysosomes and decreases storage in mucopolysaccharidosis type VII mice
about
Targeted approaches to induce immune tolerance for Pompe disease therapyReceptor-mediated endocytosis of α-galactosidase A in human podocytes in Fabry diseaseGuanidinylated neomycin mediates heparan sulfate-dependent transport of active enzymes to lysosomes.Enhancement of drug delivery: enzyme-replacement therapy for murine Morquio A syndrome.Mannose 6-phosphate receptor-mediated transport of sulfamidase across the blood-brain barrier in the newborn mouse.A breach in the blood-brain barrier.New strategies for enzyme replacement therapy for lysosomal storage diseasesDelivery of an enzyme-IGFII fusion protein to the mouse brain is therapeutic for mucopolysaccharidosis type IIIB.Enzyme therapy in mannose receptor-null mucopolysaccharidosis VII mice defines roles for the mannose 6-phosphate and mannose receptorsChallenges in design and characterization of ligand-targeted drug delivery systems.Chemically modified beta-glucuronidase crosses blood-brain barrier and clears neuronal storage in murine mucopolysaccharidosis VII.Glycosylation-independent lysosomal targeting of acid α-glucosidase enhances muscle glycogen clearance in pompe mice.Comparative binding, endocytosis, and biodistribution of antibodies and antibody-coated carriers for targeted delivery of lysosomal enzymes to ICAM-1 versus transferrin receptorInfused Fc-tagged beta-glucuronidase crosses the placenta and produces clearance of storage in utero in mucopolysaccharidosis VII mice.Targeting of the CNS in MPS-IH using a nonviral transferrin-alpha-L-iduronidase fusion gene product.Defining the pathway for Tat-mediated delivery of beta-glucuronidase in cultured cells and MPS VII mice.Enhancement of drug delivery to bone: characterization of human tissue-nonspecific alkaline phosphatase tagged with an acidic oligopeptide.Medical bioremediation of age-related diseases.Strategies for delivery of therapeutics into the central nervous system for treatment of lysosomal storage disorders.New biotechnological and nanomedicine strategies for treatment of lysosomal storage disordersInsulin-like growth factor II peptide fusion enables uptake and lysosomal delivery of α-N-acetylglucosaminidase to mucopolysaccharidosis type IIIB fibroblasts.Controlling subcellular delivery to optimize therapeutic effectCurrent and potential therapeutic strategies for mucopolysaccharidoses.Central nervous system delivery of helper-dependent canine adenovirus corrects neuropathology and behavior in mucopolysaccharidosis type VII mice.Carbohydrate-remodelled acid alpha-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice.Lipoprotein receptor binding, cellular uptake, and lysosomal delivery of fusions between the receptor-associated protein (RAP) and alpha-L-iduronidase or acid alpha-glucosidase.Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives.Targeting, endocytosis, and lysosomal delivery of active enzymes to model human neurons by ICAM-1-targeted nanocarriers.The role of immune tolerance induction in restoration of the efficacy of ERT in Pompe disease.Clearance of Heparan Sulfate and Attenuation of CNS Pathology by Intracerebroventricular BMN 250 in Sanfilippo Type B Mice.A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe diseaseGenetic engineering of IgG-glucuronidase fusion proteins.Conjugation of mannose 6-phosphate-containing oligosaccharides to acid alpha-glucosidase improves the clearance of glycogen in pompe mice.Delivery of Biologics Across the Blood-Brain Barrier with Molecular Trojan Horse Technology.Evaluation of butyrate-induced production of a mannose-6-phosphorylated therapeutic enzyme using parallel bioreactors.
P2860
Q26767363-3F2162DC-2F4F-48D0-8032-25AEA8DE0E89Q28477142-F351AB5E-25AD-457D-9E17-4989B6F40D1BQ30495726-22E9CE02-3C93-4388-96A9-6662FA484251Q33930155-273E1995-C3C5-40BD-955E-031C8AFAB474Q34015528-4C04CB19-3C4D-46DF-A10F-8945898B167BQ34078637-39E21A15-1A6D-4D4D-8DF5-40E092BC2AE1Q34157148-B971554C-7D89-4EA6-92C4-E45D85AFD558Q34384222-942D891C-796E-4B17-9F99-52DA370B4494Q35108117-134FFA34-B920-4A37-ACD1-60D5657244A4Q36346851-3724BBAB-E3B7-403D-8728-97E263CE1BBDQ36497443-516311D5-4D57-47CE-BA44-8AB04467FB7AQ36543643-30F82C7C-D5B1-4039-9D48-9E7240C6DD03Q36565901-CE963A1E-A052-4711-86CF-3CBBF87F2E5DQ36751528-EB616FEC-0F31-455E-8BB9-CE08F1A4BADFQ36953167-52C8D3C9-2C38-4DF5-82D4-CC0CC522C8EAQ36982986-C85F2B86-8E93-4D04-A5CF-2E6524E7D624Q36982989-44217230-FD76-4206-9B12-587ED89C7977Q37172423-B8D0F14B-7A53-42A3-B20A-8E7E79354472Q37672410-09C3B77A-BBFD-4475-8DFC-D9CF631C4832Q37683644-D509789F-DDA8-4AF9-931D-C4A890F5263FQ37714337-A978D8C3-9D46-4CDD-BCC7-FE97A80E4E4BQ37813021-873C3B9D-E1E3-4CAF-BFFD-72AD659CB8C7Q38194635-85AF319F-71E4-4649-892F-F106D30DF31AQ38287249-C978F359-C4C3-40EA-85E4-0E3EC8760E37Q38327807-00FC84FD-D050-4897-9872-E80C406DD8CAQ38340653-C47CB3A1-24CE-4FE2-8B59-9C9E15B5E2D3Q38684097-C867B75A-C220-4978-9D3E-5A8B9F34A39FQ38947567-B7E7DC1B-5773-4A64-BD66-340DFFF8E689Q39663434-DEDB71A2-2616-4F61-A2BE-ED8B79458FE7Q40482507-D6C7DBFC-203C-467C-B5CD-1E6B862507C7Q40499037-C330DA59-242F-48F7-B2C0-3011412E7CF4Q41011433-026B4F42-2542-4F9D-8ADC-7FE52CDFDA1CQ45071217-A5A02114-37F1-46F8-AF0A-9282D62FBEADQ47606935-EB6E0CCF-D26A-41DE-B01A-19D1891FFDADQ51751887-D6BE5FFD-92A3-4436-A2CA-E212BDD1A831
P2860
Glycosylation-independent targeting enhances enzyme delivery to lysosomes and decreases storage in mucopolysaccharidosis type VII mice
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Glycosylation-independent targ ...... olysaccharidosis type VII mice
@en
type
label
Glycosylation-independent targ ...... olysaccharidosis type VII mice
@en
prefLabel
Glycosylation-independent targ ...... olysaccharidosis type VII mice
@en
P2093
P2860
P356
P1476
Glycosylation-independent targ ...... olysaccharidosis type VII mice
@en
P2093
Carole Vogler
Deborah H Schmiel
Jeffrey H Grubb
John A Maga
Jonathan H LeBowitz
William S Sly
P2860
P304
P356
10.1073/PNAS.0308728100
P407
P577
2004-02-19T00:00:00Z